Pressroom

Improving clinical trial access and participation in Alzheimer’s disease trials could accelerate therapeutics to benefit the 1 in 10 Americans over age 65 who suffer from the condition.

While many experts believe biosimilars have the potential to lower drug costs through competitive pressure, adoption has been slower than some expected.

Treatment for COVID-19 would deliver up to $106 billion in gains by the end of 2021 a new USC Schaeffer Center analysis finds.

A USC Schaeffer study examined age-related COVID-19 risk perception among more than 6,500 American adults.

Stem cell research holds promise for generating breakthroughs against conditions including Alzheimer’s, cancer, diabetes, heart disease, vision loss—and even COVID-19.

The findings show access to Medicare coverage increases cancer detection and reduces cancer mortality. Cancer detection increased by 10% at age 65 compared to people just one or two years younger.

This letter from June 8, 2020, was penned by 30 RCMAR directors to RCMAR scientists, faculty and staff.

Analysis of March survey data sheds light on our understanding of how perceptions of the virus impact behavior.

A new USC Schaeffer Center white paper proposes an innovative strategy — pooled testing — that could lower COVID-19 testing costs for schools and businesses by half or more compared to frequent individual testing.

One-in-twelve episodes at ambulatory surgery centers had the potential to result in a surprise medical bill, according to the study.